Bayer stock reacts to Deutsche Bank and Barclays targets after FDA cancer drug approval
Published on 09/10/2026 at 15:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bayer stock (ISIN DE000BAY0017) is trading near EUR 49.00 on Xetra on September 10, 2026, as investors weigh fresh analyst targets and a new US FDA approval for the company’s lung cancer drug sevabertinib.
Analysts sharpen their view on Bayer stock
According to Zonebourse on September 10, 2026, Deutsche Bank Research has reiterated its Buy recommendation on Bayer stock and confirmed a price target of EUR 60.00, framing the five-year objectives of the Crop Science division as intact but warning that the agrochemicals business cycle remains the main risk.
In parallel, Barclays has taken a more optimistic stance on valuation: as wallstreet-online reported on September 10, 2026, the British investment bank lifted its price target for Bayer stock from EUR 60.00 to EUR 70.00 while keeping an Overweight rating, explicitly linking further upside to developments in glyphosate litigation.
FDA approval for sevabertinib adds a clinical catalyst
Beyond analyst commentary, Bayer’s pipeline delivered a tangible catalyst as the US Food and Drug Administration granted accelerated approval to sevabertinib, marketed as Hyrnuo, for a specific subset of non small cell lung cancer. According to finanzen.net on September 10, 2026, the FDA approval covers adult patients with locally advanced or metastatic HER2 mutated non squamous non small cell lung cancer, giving Bayer a new first line treatment option in a high need oncology segment.
The FDA decision is relevant for investors because oncology has been one of the growth pillars in Bayer’s pharmaceuticals business, and a first line indication typically allows for higher treatment volumes and longer duration of therapy than later line approval. At the same time, Zonebourse notes that Deutsche Bank’s analyst still highlights the cyclical nature of the Crop Science market as a key risk, suggesting that gains from sevabertinib have to be seen alongside potential volatility in the agricultural portfolio.
Stock price, volume and recent performance
Per intraday data from Xetra cited by finanzen.ch, Bayer stock traded around EUR 48.99 at approximately 12:28 on September 10, 2026, down about 0.5 percent on the day with an intraday low of EUR 48.72 and an opening price of EUR 49.20, on a volume of roughly 509,085 shares in the session.
Another snapshot from the same day shows the shares at EUR 49.03 at about 09:28 on September 10, 2026, also representing a decline of approximately 0.5 percent in Xetra trading and placing Bayer among the weaker names in the DAX 40 at that moment, according to finanzen.ch.
Crop Science strategy and risk backdrop
Deutsche Bank Research’s maintained Buy rating and EUR 60.00 target are anchored in Bayer’s long term goals for its Crop Science division. As boerse.de summarized on September 10, 2026, analyst Virginie Boucher-Ferte notes that management used a recent investor event to confirm five year targets for Crop Science and to provide more detail on how these will be achieved, but she views the agrochemicals cycle as the main remaining risk while other risk factors have largely receded.
On the legal front, glyphosate litigation remains an important theme. The higher EUR 70.00 target from Barclays explicitly ties further stock upside to progress here, with wallstreet-online highlighting that the analyst now sees more upside potential once glyphosate issues are resolved, illustrating how litigation outcomes can directly influence valuation assumptions.
Closing price context for Bayer stock
For investors, the key near term takeaway is that Bayer stock is trading in the high 48 to low 49 euro range on Xetra as of September 10, 2026, modestly below the Deutsche Bank Research target of EUR 60.00 and even further below the raised Barclays target of EUR 70.00, while a fresh FDA approval for sevabertinib strengthens the pharmaceuticals pipeline against a backdrop of cyclically exposed Crop Science earnings.
Bayer stock key data
- Company: Bayer AG
- ISIN: DE000BAY0017
- WKN: BAY001
- Ticker: BAYN
- Trading venue: Xetra
- Price (as of September 10, 2026, 12:28): 48.99 EUR
- Market capitalization: 48.99 EUR share price times outstanding shares (as of September 10, 2026)
- Sector / Industry: Healthcare, Pharmaceuticals and Crop Science
- Index membership: DAX 40
